Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      AstraZeneca's Nasal Flu Vaccine Approved In Europe


      LONDON -(Dow Jones)- AstraZeneca PLC (AZN) Tuesday said its nasal flu vaccine has been approved in Europe for children and adolescents, but is unlikely to go on sale until 2012.

      The vaccine, which is sprayed into the nose rather than given as an injection, was developed by the drug maker's U.S. unit MedImmune and is already on sale for both adults and children in the U.S. where it is known as FluMist.

      Marketing approval in Europe, where it will be called Fluenz, is for the prevention of seasonal influenza in children aged from two to less than 18 years and follows a recommendation by the London-based European Medicines Agency in October.

      "We hope that the availability of this nasal spray influenza vaccine with its novel mechanism of action will help reduce the spread of influenza," said Alex Zukiwski, M.D., executive vice president and chief medical officer of MedImmune, the biologics unit of AstraZeneca.

      The product's approval is based on a review of data from 73 global clinical studies and U.S. post-marketing studies of more than 141,000 people conducted in 38 countries. Study objectives included clinical safety and tolerability, clinical efficacy and effectiveness, and immunogenicity.

      Feb 03, 2011


      Share this Article!

    Back to top^